ProCE Banner Activity

CAO/ARO/AIO-12 and OPRA: Pooled Analysis of Watch and Wait vs Total Mesorectal Excision in Patients With Rectal Cancer Who Respond to Total Neoadjuvant Therapy

Conference Coverage
Slideset

Pooled analysis of the CAO/ARO/AIO-12 and OPRA trials suggested no differences in oncologic outcomes with a watch-and-wait approach vs mandatory total mesorectal excision in patients with stage II/III rectal cancer who responded to total neoadjuvant therapy.

Released: February 07, 2025

Expiration: August 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Exelixis, Inc., and Novartis Pharmaceuticals Corporation.

Boehringer Ingelheim Pharmaceuticals, Inc.

Exelixis, Inc.

Novartis Pharmaceuticals Corporation